Aardvark Therapeutics (AARD) Share-based Compensation (2024 - 2026)
Aardvark Therapeutics (AARD) reported Share-based Compensation of $25.9 million for Q1 2026, up 11015.88% on a YoY basis from N/an in Q1 2025, and up 1538.2% sequentially from $1.6 million in Q4 2025.
Aardvark Therapeutics (AARD) Share-based Compensation (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Share-based Compensation data on file, last reported at $25.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 11015.88% year-over-year to $25.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.9 million (up 4195.19% YoY), and the FY2025 full-year result was $18.4 million, up 4091.34% from the prior year.
- Share-based Compensation improved to $25.9 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $25.9 million in Q1 2026 to a low of $53000.0 in Q2 2024.
- A 3-year average of $3.4 million and a median of $233000.0 in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation soared 247.76% in 2025 and surged 11015.88% in 2026, its largest moves.
- Tracing AARD's Share-based Compensation over 3 years: stood at $173000.0 in 2024, then jumped by 813.87% to $1.6 million in 2025, then soared by 1538.2% to $25.9 million in 2026.
- Business Quant data shows AARD's Share-based Compensation at $25.9 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | 25.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.90 Mn |
| Mar 31, 2026 | 25.90 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 634,000.00 |
| Jun 30, 2025 | 634,000.00 |
| Mar 31, 2025 | 233,000.00 |
| Mar 31, 2025 | 233,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |